argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis

Wednesday, May 3, 2017 1 min read

Key Takeaway: argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis

Full Press Release Details

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis.